Phase IIa trial to evaluate the pharmacokinetic response to bactericidal/permeability-increasing protein (rBPI21 [opebacan]) for the treatment of patients with burn injury

Next Previous
Trial Profile

Phase IIa trial to evaluate the pharmacokinetic response to bactericidal/permeability-increasing protein (rBPI21 [opebacan]) for the treatment of patients with burn injury

Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2008

At a glance

  • Drugs Opebacan (Primary)
  • Indications Bacterial infections; Wound infections
  • Focus Pharmacokinetics

    • Most Recent Events

    • 02 Jun 2008 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 05 Jul 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top